The Saga Continues: Ethan Perlstein, Indie Scientist, Part 3

Ethan Perlstein, Founder and CEO of Perlara (former Perlstein Lab)

Chapters:

0:00 Disabusing ourselves of the notion scientist equals professor

3:46 Working directly with patients to do bottom up drug discovery

10:09 Novartis buy-in

12:18 How was Y Combinator for a biotech startup?

16:37 What has it meant so far to be a PBC?

21:23 Have you seen other scientists go your path?

Today Ethan Perlstein joins us on the program for a third time. His path as a ‘rogue scientist’ has become a bit of a case study here at Mendelspod as we look into alternate paths for scientists and for drug development.

When Ethan was first on the program, he’d just declared his independence, or break from the world of academia. He urged other scientists to do the same and to take to social media to upend a system that was creating the “postdocalypse.” And he didn’t just take a job working for big pharma. He wanted to carry on with the science that intrigued him: a new model of drug discovery.

The second time we featured Ethan he was set up at the QB3 incubator space in San Francisco as the Perlstein Lab, a hybrid of academic lab and regular biotech startup. He had secured some seed funding, and hired five scientists. It was then that he announced a new drug discovery platform using simple animal models (yeast, frutiflies, worms) that would provide proof of concept at a much lower price than what you see with traditional biotechs and pharma.

That was in 2014. Now, at the end of 2016 Ethan has some updates to share. Last month he announced a licensing and investment deal with the drug giant Novartis. He can boast of his first drug candidate, Per101. And he’s a graduate of the Silicon Valley’s business maker, the well known Y Combinator.

Ethan says the Novartis deal is more than just his first revenue generator, it validates the platform of using simple animal models. The deal also boosts what he calls his precision 'business development model.”

“People talk about precision medicine, but they don’t ever talk about precision business development. And that part of the discussion is critical, because you need to think about not only the science that gets the job done, but how the company practically gets put together.”

Working on rare diseases, Ethan is going directly to patients, albeit rich ones at first, with a low cost drug discovery method, creating a new business model that cuts past traditional funding partners and offers a somewhat more academic setting. Perlara, the newest name for Perlstein Lab, is a public benefit corporation.

What was Ethan's experience at the tech dominated Y Combinator? How has being a public benefit corp impacted his decisions this past year? And, come on, if he looks, smells, and acts like a regular old biotech entrepreneur, is he still a rogue scientist?

Here it is. The Indie Scientist, Part 3.




New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup